Specialty pharmaceutical company Meda is being acquired by Mylan, expanding Mylan's reach into emerging markets, building on its recent specialty and branded generics acquisitions and creating an OTC division worth about $1 billion.
McKesson's North America pharmaceutical distribution and services revenues were $39.6 billion for the quarter, up 6% on a reported basis and 7% on a constant currency basis, primarily driven by market growth.
Shire and Baxalta, according to a report in Crain’s Chicago Business, will be merging in a deal that is being valued at about $32 billion, which includes a pledge from Shire to give Baxalta Shareholders $18 cash, plus .1282 of Shire’s American depository receipts, per share. The merger will make Shire the largest maker of treatments for rare diseases in the world. (Crain’s Chicago Business)